Search
Alzheimer's Disease Paid Clinical Trials in Illinois
A listing of 26 Alzheimer's Disease clinical trials in Illinois actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 26
The state of Illinois currently has 26 active clinical trials seeking participants for Alzheimer's Disease research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Transcranial Magnetic Stimulation (TMS) for Obsessive Compulsive Disorder (OCD)
Recruiting
Transcranial magnetic stimulation (TMS) is an FDA-approved, non-invasive form of brain stimulation for OCD. TMS has been shown to be an effective form of treatment in individuals with OCD. By using a form of TMS termed theta-burst stimulation (TBS), we hope that this will result in a more effective treatment by producing faster symptom reduction. We are trialing a novel form of accelerated TMS, where we will deliver ten 10-minute sessions per day, for 5 days. This study will compare the efficacy of TMS for OCD at two distinct brain regions. Participants will be randomized into one of two study groups, and receive stimulation at either the DMPFC or R-OFC. Both regions have been linked to OCD by research. Patients that don't respond to their study region will have the option to receive stimulation at the other region.
Conditions:
Obsessive-Compulsive Disorder
Obsessive Compulsive Disorder
Obsessive Compulsive Disorder (OCD)
Obsessive-Compulsive Disorder (OCD)
Obsessive-compulsive Disorders and Symptoms
Featured Trial
Depression Clinical Studies
Recruiting
Need new medication for depression? Help us study an investigational medication to potentially help people with MDD. Qualified participants may receive reasonable compensation for trial-required travel expenses.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorder
Featured Trial
Bipolar Disorder Study (Medicare Required)
Recruiting
Non-drug Bipolar Depression study for adults with Medicare. If you have Bipolar Disorder, are over the age of 18, and are currently depressed, you may be eligible to take part in this study. If you have tried at least four treatments and not found them helpful, you are a good candidate for this study. All study-related care will be provided at no cost to you.
Conditions:
Bipolar Disorder
Bipolar Depression
Bipolar I Disorder
Depression
Bipolar
Featured Trial
Child/Teen Migraine
Recruiting
The study is evaluating an investigational product for the treatment of migraine in children the ages of 6 to 17. The investigational product is currently approved to treat migraines in adults.
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Recruiting
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's disease (AD).
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
06/20/2024
Locations: Great Lakes Clinical Trials - Andersonville, Chicago, Illinois +1 locations
Conditions: Alzheimer's Disease
Alzheimer's Disease Neuroimaging Initiative 4
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/19/2024
Locations: Northwestern University, Chicago, Illinois +1 locations
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/19/2024
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
ACP-204 in Adults With Alzheimer's Disease Psychosis
Recruiting
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP
Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first.
Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B will b... Read More
Gender:
All
Ages:
Between 55 years and 95 years
Trial Updated:
06/18/2024
Locations: Revive Research Institute, Inc., Elgin, Illinois
Conditions: Alzheimer's Disease Psychosis
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
Recruiting
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
06/17/2024
Locations: Southern Illinois University, Springfield, Illinois
Conditions: Alzheimer Disease
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 65 years and 80 years
Trial Updated:
06/17/2024
Locations: IMA Clinical Research - Chicago, Chicago, Illinois +8 locations
Conditions: Alzheimer Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Recruiting
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease.
The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason and safety and tolerability in subjects wit... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/17/2024
Locations: Clinical Trial Site, Berwyn, Illinois
Conditions: Psychosis Associated With Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/17/2024
Locations: Clinical Trial Site, Elgin, Illinois
Conditions: Psychosis Associated With Alzheimer's Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
06/13/2024
Locations: Great Lakes Clinical Trials, Chicago, Illinois +5 locations
Conditions: Alzheimer Disease, Early Onset
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
Recruiting
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/06/2024
Locations: Re:Cognition Health - Chicago, Chicago, Illinois
Conditions: Alzheimer Disease
A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
Recruiting
The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/29/2024
Locations: Office of Jeffrey S. Ross, MD, Northbrook, Illinois
Conditions: Alzheimer Disease
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Recruiting
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.
Gender:
All
Ages:
Between 40 years and 64 years
Trial Updated:
05/23/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
1 - 12 of 26